Videos and News

Goodbody Health Group Updates

See a selection of our recent news and updates.
Goodbody Health CEO George Thomas discusses CBD plant sale
December, 2022

CEO George Thomas talks to Proactive about the sale of the CBD extraction plant and what this means for the Goodbody Health business in 2023 and beyond.

CEO George Thomas talks 2023 strategy for Goodbody Health
December, 2022

With an increasing need for affordable, convenient, community based health testing, Goodbody is well-poised to support customers to Know More and Live Better.

Why is Britain lagging on cancer care?

With the pressures placed on the NHS, who are now operating a ’late diagnosis service’ for cancer, there has never been a better time to start looking after our health starting with general self-care before symptoms appear through our blood testing services.


Tests such as our Goodbody Hereditary Cancer Genetic Tests , which are DNA tests which determine whether you have a genetic mutation which makes you prone to developing cancer, are an excellent way you can identify your risks and monitor your health while considering lifestyle changes to reduce those risks.” Marc Howells, CEO Goodbody Health.

Introduction to Goodbody Health
Goodbody Health progress
September, 2022

Marc Howells, Chief Executive Officer of the Goodbody Health Group discusses progress so far in 2022, as well as addressing stake holder questions.

Heart and Circulatory Diseases
5th July, 2022



Heart and Circulatory Diseases 5th July 2022 Marc talks about the impact of heart and circulatory diseases.

Goodbody Health discusses its switch to a listing in London
13th June, 2022

Geremy Thomas, executive chairman, explains why Goodbody Health is switching its listing from Canada to London.

It’s hard to justify the cost of being in Vancouver, he says, and with cash king at the moment the money can be used to invest in its clinics in the UK, which will be focused on blood tests and wellness now that Covid-19 is easing.

All around, the target is to cut unnecessary expenses, he adds.

Why is the outlook for Goodbody Health ‘tremendously exciting and hugely positive’
27th May, 2022

Marc shares his views on a under resourced and over burdened NHS, a change in how people manage their health, how Goodbody Health is meeting the massive growing demand for its services and can the company continue to grow at such speed.

Goodbody Health products included on the FSA Novel Foods Register
31st March, 2022

George explains the submission process, what the FSA Public list announcement means, what it means for Goodbody and the implication this has for consumers.

A Blood MOT to prevent heart disease
11th March, 2022

George shares his thoughts on whether people are taking heart health seriously enough, if they need to be more proactive in managing their heart health, what a blood MOT consist of and the experience Goodbody Health has built-up in blood testing.

CSE Issue Update
21st February, 2022

Founder Geremy Thomas, talking with the Canadian Securities Exchange.

Early detection substantially improves outcomes
21st February, 2022

Goodbody Health Inc. Scientific Advisory Committee Member Dr Jamie Brosch joins DirectorsTalk Interviews to share his views on the company.


Hargreaves Lansdown Electronic Trading Issue
18th February, 2022

Many of our shareholders who hold Goodbody Health shares through Hargreaves Lansdown have shown frustration that they cannot trade electronically.

We have tried on your behalf to rectify this situation with Hargreaves Lansdown. Although we know we are not the only company for whom their electronic platform is unavailable we still feel this needs to be rectified, as they are one of the largest platforms. Our shares can be traded electronically on a number of platforms as detailed on our website We have been asked repeatedly to resolve the situation with Hargreaves Lansdowne and it has even been suggested on many occasions that our share price may be affected by this issue which is why we are keen to elicit your influence to resolve this matter.

What may help is if our shareholders who trade through Hargreaves Lansdowne raise this as a concern with them. If you would like this rectified, please express your views on the matter to:

Hargreaves Lansdown Investment Helpdesk: 0117 900 9000
Monday – Friday: 8am – 5pm
Saturday: 9.30am – 12.30pm

Goodbody Health to help prevent type 2 diabetes through blood glucose level checks
11th February, 2022

According to Diabetes UK, at the moment 13.6 million people are at increased risk of type 2 diabetes in the UK. If you don’t have it yet, and with the right support, up to 50% of cases of type 2 diabetes can be prevented or delayed.

Blood testing opens up market for early Cancer detection
8th February, 2022

The Sunday Times reported on the 6 February 2022 that a new blood testing technique due to be introduced by the NHS will determine how likely a patient is to have cancer. 

Goodbody Health Group aligned with NICE innovation agenda
2nd February, 2022

The Board of The National Institute for Health and Care Excellence (NICE), provided an update on 20th January 2022 on how it plans to evaluate promising new health technologies and making patient access fairer. 


Goodbody Health-a pivotal moment in community pharmacy
26th January 2022

Ian Strachan, Scientific Advisory Committee Member talks about Goodbody Health.

Sativa Wellness Group change name to Goodbody Health Inc. reflecting 'Know more - Live better' ethos
12th January 2022

Sativa Wellness Group inc. have changed its name to Goodbody Health Inc, adopting the name of its main brand. The new ticker symbol on the AQSE Growth Market and Canadian Securities Exchange will be GBDY. This follows the firm’s successes of 2021 in delivering health…

Investor presentation with CEO, Marc Howells
12th January 2022

Marc Howells, Chief Executive Officer talks through the investor presentation. 

Goodbody Health Group featured on the news. financial website
1st October, 2021

Sativa Wellness Group Inc have been recently featured on the website in an interesting article written by Stefan Feulner.
A link to this article can be found below.

Sativa Wellness Group exceptionally strong results (Interview)
13th August, 2021

Sativa Wellness Group inc. (LON:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk Interviews to discuss its first quarterly profit in Q2 2021. Geremy talks us through the results highlights and explains the companies plans for the second half.

Sativa Wellness Group revenues soar, achieving their goal of opening 30 Covid-19 testing stores
26th May, 2021

Sativa Wellness Group Inc’s (LON:SWEL) (CSE: SWEI) Geremy Thomas talks to Proactive London’s Katie Pilbeam about their Q1 2021 financial statements.

PhytoVista Laboratories receive accreditation for testing of cannabinoids
23rd April, 2021

Sativa Wellness Group Inc’s (LON:SWEL) Geremy Thomas talks to Proactive London’s Katie Pilbeam about subsidiary PhytoVista Laboratories , which has been was granted ISO/IEC 17025:2017 accreditation from the UK for the testing of cannabinoids.

Sativa Wellness Group Extends its reach in COVID testing (DirectorsTalk)
7th April 2021

Sativa Wellness Group Inc. (LON:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk to discuss now being listed on the UK government website to offer 2 and 8 day quarantine tests. Geremy explains where they are with the clinic roll-out and how this will impact revenues.

Sativa Wellness Looking To Deliver Covid-19 Jabs From 30 UK Locations
by BusinessCann
15th March, 2021

SATIVA Wellness’ pivot to Covid-19 testing work has exceeded expectations with plans afoot to open up a dozen new locations delivering blood tests, vaccines and vaccine boosters.
Previously know as The Sativa Group the name change to Sativa Wellness in October last year reflected its efforts in the fight against the pandemic.
read more…

Sativa Wellness Group expect a significant ramp up (Interview)
11th March, 2021

Sativa Wellness Group Inc. (AQSE:SWEL / CNSX:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk Interviews to discuss reaching its £1m milestone for COVID testing. Geremy talks us through the milestone, the addition of further testing clinics including two mobile units, the significance of having 30 clinics to the company and how long Geremy thinks the PCR testing revenue stream will last.

Sativa Wellness Group on target to achieve 30 Covid-19 clinics by end of April after £1m milestone
10th March, 2021

Sativa Wellness Group Inc’s (LON:SWEL) Geremy Thomas talks to Proactive London’s Katie Pilbeam about its coronavirus (COVID-19) testing business which has now achieved over £1.1mln worth of bookings in less than four months since opening its first clinic in Bath, UK.

The company now has 17 operational clinics throughout the UK testing for COVID-19, in line with its target to have 30 clinics by the end of April.

Sativa seed to shelf CBD journey that the market can rely on
2nd March, 2021

Sativa Wellness Group Inc. (AQSE:SWEL / CNSX:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk to discuss its operations meeting the requirements of Good Manufacturing Practice and Good Hygiene Practice standards for food manufacturing. Geremy explains what this means for the company, the impact this has on the Novel Foods accreditation and now with David Beckham as a competitor, how he feels about that.

Sativa to focus on opportunities that will bring in profit and add value to company
22nd February 2021

Sativa Wellness Group Inc’s (LON:SWEL) Geremy Thomas talks to Proactive London about being back at the helm with his focus on generating cash and profit as well as reducing costs.

He says, ‘since I’ve been in place we’ve seen a doubling of our share price and I think that will continue to rise‘.

FSA regulation key to industry and to the company
February 19, 2021

Sativa Wellness Group Inc. (CNSX:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk Interviews to discuss its novel food application to the FSA. Geremy explains why he has re-joined the board, the significance of the application announcement and the recent success of new listings in this CBD sector.

Play Video
Sativa delighted with Cenkos appointment as it opens CBD wellness centre
July 3, 2019

Sativa Group PLC‘s (LON:SATI) Geremy Thomas caught up with Proactive London’s Andrew Scott following the opening of their first cannabidiol (CBD) wellness retail outlet in Bath at the weekend.

The Goodbody Wellness store was launched on Friday evening by Crispin Blunt, MP for Reigate and co-chair of the All Party Parliamentary Group for Drug Policy Reform.

Sativa Investments 'at the forefront' of developing UK medical cannabis market
Janurary 10, 2019

Geremy Thomas, founder and chief executive of Sativa Investments PLC (LON:SATI), caught up with Proactive London’s Andrew Scott to discuss the NEX-based medical cannabis investor’s trading and strategic update.

Sativa’s this week unveiled plans to become a first-mover seed-to-consumer business in the UK.

Sativa Investments PLC acquires UK-based PhytoVista Laboratories
July 3, 2018

Geremy Thomas, chief executive of Sativa Investments PLC (NEX:SATI), tells Proactive’s Andrew Scott they’ve agreed to buy PhytoVista Laboratories, a UK-based lab that tests cannabis oils and hemp products, for £435,000.

Sativa Investments has "unique" market position for UK cannabis investors
May 23, 2018

Sativa Investments PLC’s Geremy Thomas tells Proactive that the medicinal cannabis market has seen explosive growth all over the world, particularly in Vancouver, Canada.

He adds that Sativa has a unique position in the UK market that allows UK investors to benefit from companies in regulated markets.